OTC · USD
HRGN
Sign in to followHarvard Apparatus Regenerative Technology, Inc.
Export transactions ↓Last 12 months
Inside the activity.
3 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 2 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2018 Filed Jun 7, 2018 21:02 UTC |
Yu HongPresident
|
GrantStock Option (right to buy) · Derivative | 104,643 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001144204-18-033283 · tv496101_form4.xml · derivative · entry 2 Yu Hong · CIK 0001743047 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,643 Underlying: Common Stock, par value $0.01 per share · 104,643 shares Expires 2028-05-29 F2 · derivative.exercise_date: Non-Qualified Stock Option shares vest based on certain performance milestones. Read SEC document |
| May 29, 2018 Filed Jun 7, 2018 21:02 UTC |
Yu HongPresident
|
GrantStock Option (right to buy) · Derivative | 104,643 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001144204-18-033283 · tv496101_form4.xml · derivative · entry 1 Yu Hong · CIK 0001743047 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,643 Underlying: Common Stock, par value $0.01 per share · 104,643 shares Expires 2028-05-29 F1 · derivative.exercise_date: Incentive Stock Option shares vest in four equal installments on December 31, 2018, 2019, 2020 and 2021. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:14 UTC |
McKee Blaine H.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 912 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017605 · tv489777_form4.xml · derivative · entry 2 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:14 UTC |
McKee Blaine H.Director
|
Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017605 · tv489777_form4.xml · nonDerivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:06 UTC |
McNaughton ThomasChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 928 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017587 · tv489774_form4.xml · derivative · entry 2 McNaughton Thomas · CIK 0001449450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,784 Underlying: Common Stock · 928 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:06 UTC |
McNaughton ThomasChief Financial Officer
|
Exercise / conversionCommon Stock | 928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017587 · tv489774_form4.xml · nonDerivative · entry 1 McNaughton Thomas · CIK 0001449450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:11 UTC |
Robinson Thomas HDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 912 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017597 · tv489776_form4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:11 UTC |
Robinson Thomas HDirector
|
Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017597 · tv489776_form4.xml · nonDerivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 21:08 UTC |
McGorry James JosephDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,650 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017592 · tv489775_form4.xml · derivative · entry 2 McGorry James Joseph · CIK 0001573147 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 Underlying: Common Stock · 1,650 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 21:08 UTC |
McGorry James JosephDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 1,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017592 · tv489775_form4.xml · nonDerivative · entry 1 McGorry James Joseph · CIK 0001573147 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 21:03 UTC |
Canepa John JDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 912 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017584 · tv489773_form4.xml · derivative · entry 2 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 21:03 UTC |
Canepa John JDirector
|
Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017584 · tv489773_form4.xml · nonDerivative · entry 1 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:31 UTC |
DST Capital LLC10% owner
|
PurchaseCommon Stock | 10,000 | $3.26 | $32,600.00 |
DisclosureSEC source: 0001144204-18-012556 · tv487576_4.xml · nonDerivative · entry 1 DST Capital LLC · CIK 0001727656 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by sole member of reporting person Disclosed balance after: 25,722 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.016 to $3.30, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 23:40 UTC |
DST Capital LLC10% owner
|
PurchaseCommon Stock | 1,572 | $2.67 | $4,197.24 |
DisclosureSEC source: 0001144204-18-003347 · tv483929_4.xml · nonDerivative · entry 1 DST Capital LLC · CIK 0001727656 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by sole member of reporting person Disclosed balance after: 15,722 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.594 to $2.70, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 19, 2018 Filed Jan 22, 2018 21:22 UTC |
DST Capital LLC10% owner
|
PurchaseCommon Stock | 3,700 | $2.60 | $9,620.00 |
DisclosureSEC source: 0001144204-18-003086 · tv483793_form4.xml · nonDerivative · entry 2 DST Capital LLC · CIK 0001727656 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by sole member of reporting person Disclosed balance after: 14,150 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.5999 to $2.60, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 22, 2018 21:22 UTC |
DST Capital LLC10% owner
|
PurchaseCommon Stock | 5,000 | $2.20 | $11,000.00 |
DisclosureSEC source: 0001144204-18-003086 · tv483793_form4.xml · nonDerivative · entry 1 DST Capital LLC · CIK 0001727656 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by sole member of reporting person Disclosed balance after: 10,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.152 to $2.20, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:15 UTC |
DST Capital LLC10% owner
|
PurchaseCommon Stock | 5,000 | $2.16 | $10,800.00 |
DisclosureSEC source: 0001144204-18-002289 · tv483371_form4.xml · nonDerivative · entry 2 DST Capital LLC · CIK 0001727656 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by sole member of reporting person Disclosed balance after: 5,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.04 to $2.19, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 21:15 UTC |
DST Capital LLC10% owner
|
PurchaseCommon Stock | 200 | $1.90 | $380.00 |
DisclosureSEC source: 0001144204-18-002289 · tv483371_form4.xml · nonDerivative · entry 1 DST Capital LLC · CIK 0001727656 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by sole member of reporting person Disclosed balance after: 450 Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 08:00 UTC |
LaFrancesca SaverioDirector · President and CMO
|
PurchaseCommon Stock | 100,000 | $0.37 | $37,000.00 |
DisclosureSEC source: 0001144204-17-045073 · v474033_4.xml · nonDerivative · entry 1 LaFrancesca Saverio · CIK 0001641900 · Director · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,998 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 08:01 UTC |
LaFrancesca SaverioDirector · President and CMO
|
PurchaseCommon Stock | 150,000 | $0.32 | $48,000.00 |
DisclosureSEC source: 0001144204-17-044867 · v473946_form4.xml · nonDerivative · entry 1 LaFrancesca Saverio · CIK 0001641900 · Director · President and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,998 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.29 to $0.34, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:17 UTC |
KENNEDY JOHN FDirector
|
GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015095 · v461955_4.xml · derivative · entry 2 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:17 UTC |
KENNEDY JOHN FDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015095 · v461955_4.xml · derivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:16 UTC |
McKee Blaine H.Director
|
GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015091 · v461952_4.xml · derivative · entry 2 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:16 UTC |
McKee Blaine H.Director
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015091 · v461952_4.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:17 UTC |
LaFrancesca SaverioSee Remarks
|
GrantRestricted Stock Units · Derivative | 107,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015097 · v461956_4.xml · derivative · entry 2 LaFrancesca Saverio · CIK 0001641900 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,250 Underlying: Common Stock, par value $0.01 per share · 107,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in four equal installments on March 14, 2018, 2019, 2020 and 2021. F3 · derivative.expiration_date: The restricted stock units vest and settle in four equal installments on March 14, 2018, 2019, 2020 and 2021. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:17 UTC |
LaFrancesca SaverioSee Remarks
|
GrantStock Option (right to buy) · Derivative | 217,750 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015097 · v461956_4.xml · derivative · entry 1 LaFrancesca Saverio · CIK 0001641900 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,750 Underlying: Common Stock, par value $0.01 per share · 217,750 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in four equal installments on March 14, 2018, 2019, 2020 and 2021. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:19 UTC |
McNaughton ThomasChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 74,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015099 · v461957_4.xml · derivative · entry 2 McNaughton Thomas · CIK 0001449450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,250 Underlying: Common Stock, par value $0.01 per share · 74,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in four equal installments on March 14, 2018, 2019, 2020 and 2021. F3 · derivative.expiration_date: The restricted stock units vest and settle in four equal installments on March 14, 2018, 2019, 2020 and 2021. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:19 UTC |
McNaughton ThomasChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 150,750 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015099 · v461957_4.xml · derivative · entry 1 McNaughton Thomas · CIK 0001449450 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,750 Underlying: Common Stock, par value $0.01 per share · 150,750 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in four equal installments on March 14, 2018, 2019, 2020 and 2021. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:21 UTC |
Robinson Thomas HDirector
|
GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015103 · v461958_4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:21 UTC |
Robinson Thomas HDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015103 · v461958_4.xml · derivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:16 UTC |
Canepa John JDirector
|
GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015094 · v461954_4.xml · derivative · entry 2 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:16 UTC |
Canepa John JDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015094 · v461954_4.xml · derivative · entry 1 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:16 UTC |
McGorry James JosephDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 132,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015093 · v461953_4.xml · derivative · entry 2 McGorry James Joseph · CIK 0001573147 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock, par value $0.01 per share · 132,000 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in four equal installments on March 14, 2018, 2019, 2020 and 2021. F3 · derivative.expiration_date: The restricted stock units vest and settle in four equal installments on March 14, 2018, 2019, 2020 and 2021. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:16 UTC |
McGorry James JosephDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 268,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015093 · v461953_4.xml · derivative · entry 1 McGorry James Joseph · CIK 0001573147 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,000 Underlying: Common Stock, par value $0.01 per share · 268,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in four equal installments on March 14, 2018, 2019, 2020 and 2021. Read SEC document |
| October 12, 2016 Filed Oct 14, 2016 12:00 UTC |
DerSimonian HaroutChief Scientific Officer
|
PurchaseCommon Stock | 10,000 | $0.91 | $9,100.00 |
DisclosureSEC source: 0001144204-16-128079 · v450526_form4.xml · nonDerivative · entry 1 DerSimonian Harout · CIK 0001680625 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.